Objective To evaluate the clinical application of metoprolol trimetazidine therapeutic effect of coronary heart disease heart failure .Methods From January 2014 to January 2015 admitted 120 cases of coronary heart disease with heart failure .The patients and their families agreed Ethics Committee approval.The patients were randomly divided into control group and observation group , 60 patients in each group , observation group using a single metoprolol treatment , the control group on the basis of the observation group , plus the United trimetazidine treatment .Treatment for 6 months , compared two groups of improving cardiac function of the conditions and treatment .Results The total effective rate was 96.6%(58/60), the observation group was significantly higher than the 66.6%(40/60) (P<0.05). After treatment , the control group after treatment of heart rate , systolic blood pressure , and left ventricular ejection surface and other parties are superior to observation group , ( P <0.05 ) .Conclusion The clinical application of metoprolol Hydrochloride Trimetazidine treatment of coronary heart disease complicated by heart failure treatment is safe and effective in improving cardiac function in patients , worthy of promotion .%目的：探讨临床应用美托洛尔联合曲美他嗪治疗冠心病心力衰竭的治疗效果。方法将汉川市人民医院2014年1月—2015年1月收治的120例冠心病心力衰竭患者，经患者及家属同意，伦理委员会批准，按数字分组法随机分为对照组与观察组，每组60例患者，观察组单一采用美托洛尔治疗，对照组在观察组的基础上，加用联合曲美他嗪治疗。疗程为6个月，对比两组的心脏各项功能的改善情况及治疗效果。结果对照组总有效率为96．6％（58／60），明显高于观察组的66．6％（40／60）（P＜0．05）。对照组治疗后心率、收缩压和左心室射血等方面均优于观察组，（ P＜0．05）。结论临床上应用美托洛尔联合盐酸曲美他嗪治疗疗冠心病并发心力衰竭，安全有效，对改善患者心功能效果显著，值得推广。
展开▼
